PTPN2 and melanoma: Despite no PTPN2 inhibitors having been extensively studied to date, the previously reported promising results revealing the oncogenic role of PTPN2 strongly suggest the necessity to design selective inhibitors of this phosphatase in order to potentiate the sensitivity of melanoma to the effects of immunotherapy.